Genprex , Inc., a pharmaceutical company based in Austin, Texas, has received notifications from The Nasdaq Stock Market indicating non-compliance with certain listing requirements. Currently trading ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
as maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the S Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene ...
7) Amgen's Imdelltra/Imdylltra (tarlatamab), DLL3×CD3-targeting bispecific T-cell engager (BiTE) for extensive stage small cell lung cancer (ES-SCLC), the first DLL3-directed therapy to reach the ...
RayzeBio’s pipeline includes SSTR2-targeting RYZ101, in phase 3 for NETs and phase 2 for extensive-stage small cell lung cancer (ES-SCLC), along with GPC3 and CA9 candidates in early-stage ...
ComingSoon on MSN4d
Who Is Charlie Kirk's Wife? Erika Frantzve's Job & Relationship HistoryConservative activist and co-founder of Turning Point USA, Charlie Kirk, is no stranger to the public eye but not much is known of his wife. While his professional work has often dominated headlines, ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
Why is Christian Science in our name? Our name is about honesty. The Monitor is owned by The Christian Science Church, and we’ve always been transparent about that. The Church publishes the ...
An Academic Perspective to First-Line Treatment Decisions for EGFR-mutated Advanced/Metastatic NSCLC
The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular ...
Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient presents to her primary care physician (PCP) with continued dry cough, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback